ARCH Venture Partners

ARCH Venture Partners Research Overview ARCH Venture Partners is one of the world's leading venture capital firms focused exclusively on early-stage, breakthrough discoveries in life sciences, deep science, and information technology. Founded in 1997 and headquartered in Chicago, Illinois, with a secondary office in Seattle, Washington, ARCH has established itself as the premier builder of transformative companies at the concept stage. The firm manages approximately $12 billion in assets under management and operates Fund XIII, a $3+ billion fund closed in September 2024, focused on co-founding and building revolutionary life sciences and deep-science platforms directly with university researchers and scientists. Investment Thesis & Philosophy ARCH's core philosophy is revolutionary and contrarian. The firm is explicitly not interested in following the crowd and positions itself as contrarian, bold, and imaginative risk takers who follow the science to found companies based on revolutionary technologies that can impact people's lives. Unlike traditional venture firms that wait for entrepreneurs to approach them, ARCH actively co-founds companies by identifying breakthrough science, recruiting world-class management teams, and providing patient capital to build long-term value. ARCH's distinctive approach centers on science-first investing with deep scientific due diligence before company formation, direct company formation with university researchers and scientists, long-term commitment with patient capital from concept stage, flexibility in sizing investments based on opportunity rather than fund constraints, and leveraging an extended partnership network to build companies through formation and growth stages. Investment Focus & Sectors ARCH's sector focus is heavily concentrated in three primary areas: Life Sciences and Biotech (primary focus including therapeutics, precision medicine, diagnostics, medical devices), Deep Science and Physical Sciences (biotechnology platforms, genomics, computational biology, quantum computing), and Enabling Technology (healthcare IT, cloud infrastructure). The firm operates sector-agnostically within these broad areas with demonstrated investments across oncology, neurology, immunology, rare disease, cardiovascular disease, infectious disease, and emerging therapeutic modalities including gene therapy, CRISPR base editing, and synthetic biology. Stage Focus & Check Size ARCH's primary investment focus is Seed stage, with secondary emphasis on Series A and substantial follow-on capability throughout company development. Check size ranges from $500K-$5M for initial seed investments, with a historical range of $50K to hundreds of millions per company across the full portfolio lifetime as companies grow. Fund XIII commands $3+ billion with total assets under management of approximately $12 billion. Lead Tendency & Decision Process ARCH leads rounds consistently. The firm typically leads seed-stage investments in companies it founds or identifies early. Decision-making operates through a partnership model of deep life sciences experts, entrepreneurs, and business operators led by Co-founder Robert Nelsen (Pioneer in biotech with 150+ companies sourced), Co-founder Keith Crandell, Managing Director Kristina Burow (recognized as top woman in biopharma), and others with 30+ years of combined biotech investing experience. Geographic Focus Primary US focus with major offices in Chicago (headquarters), Seattle, San Francisco, Cambridge, and San Diego. ARCH also maintains selected international investments in Europe, China, and Asia-Pacific with portfolio companies in Cambridge UK, Shanghai, Suzhou, Hong Kong, and Singapore. Recent Activity & Fund Status ARCH is actively deploying from Fund XIII with 13 new investments in 2025 and continuing activity into 2026. Recent notable exits include Bristol Myers Squibb's acquisition of Orbital Therapeutics (October 2025) for $1.5 billion. Portfolio includes 279 companies as of January 2026 with 50+ reaching $1 billion valuations. Portfolio companies including Seaport Therapeutics (Fierce 15 list), Dispatch Bio (Endpoints 11 list), and Bit Bio (January 2026) demonstrate consistent momentum. Team & Leadership ARCH's leadership is world-class and deeply embedded in the biotech ecosystem. Core team includes 5 managing directors with specialized expertise, 9+ partners, and 15+ venture partners including accomplished entrepreneurs, pharma executives, and leading scientists providing deep domain expertise and operational support. Summary ARCH Venture Partners is the gold standard for deep-science biotech investing at the earliest stages. With over 30 years of biotech investing experience, 150+ company-building expertise, and managing $12 billion in assets, ARCH remains the premier choice for visionary scientists and entrepreneurs seeking to build transformational life sciences companies. The firm's contrarian philosophy, science-first approach, and commitment to co-founding breakthrough companies with leading researchers make it ideal for exceptional science and founder teams ready for deep partnership.